(ATH) – Company Press Releases
-
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
-
Athene Prices $1,000,000,000 Investment Grade Senior Notes Offering
-
Athabasca Oil Announces Renewal of Normal Course Issuer Bid
-
Athene Prices $500 Million Investment Grade Junior Subordinated Debentures Offering
-
Athabasca Oil Announces 2023 Year-end Results & Reserves and Plans to Renew Annual Share Buyback Program
-
Athabasca Oil Announces Closing of “Duvernay Energy Corporation” with Cenovus Energy and Provides Updated 2024 Guidance
-
Athabasca Oil Announces Creation of “Duvernay Energy Corporation” with Cenovus Energy to Accelerate Value in the Prolific Kaybob Duvernay Play
-
Athene Prices $600 Million Investment Grade Notes Offering
-
Athabasca Oil Announces 2024 Budget and Return of Capital Update
-
Athene Executes Block Reinsurance Transaction in Japan
-
Athabasca Oil Announces 2023 Third Quarter Results with Record Adjusted Funds Flow, Free Cash Flow and Leismer Production along with Continued Share Buybacks
-
Athabasca Oil Corporation Announces Closing of Non-Core Light Oil Asset Sale, Reaffirms 2023 Guidance and Provides a Return of Capital Update
-
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund
-
Athabasca Oil Corporation Announces Sale of Non-Core Light Oil Assets for $160 Million; Retains Strategic Duvernay Assets with 500 Future Drilling Locations
-
Athabasca Oil Announces 2023 Second Quarter Results
-
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
-
Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023
-
Athabasca Oil Provides Alberta Wildfire Update
-
Athabasca Oil Corporation Announces Results from 2023 Annual Shareholder Meeting
-
Athabasca Oil Announces 2023 First Quarter Results and Execution on its Return of Capital Commitment through Inaugural Share Repurchases
-
Athene Announces Fixed Income Investor Conference Call
-
Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology
-
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
-
Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
-
Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
-
Athabasca Oil Announces Approval of Normal Course Issuer Bid
-
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
-
Athabasca Oil Announces 2022 Year-end Results & Reserves, Record Cash Flow and Plans to Execute a Share Buyback Program
-
Athene Holding Ltd. Declares First Quarter 2023 Preferred Stock Dividends
-
Alterity Therapeutics Receives Regulatory Authorization in France and Austria to Proceed with ATH434 Phase 2 Clinical Trial
-
Athene Announces Fixed Income Investor Conference Call
-
Athene Announces $2 Billion First Close For Apollo / Athene Dedicated Investment Program II
-
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
-
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
-
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
-
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
-
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)
-
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
-
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office
-
Athabasca Oil Announces 2023 Budget and Return of Capital Strategy
-
Athene Holding Ltd. Declares Fourth Quarter 2022 Preferred Stock Dividends
-
LeasePlan USA and Wheels Donlen Complete Combination to Create Corporate Mobility Solutions Leader
-
Athene Prices $400 Million Investment Grade Notes Offering
-
Athene Prices $400 Million Investment Grade Notes Offering
-
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting
-
Athabasca Oil Announces 2022 Third Quarter Results including Record $102 million of Adjusted Funds Flow along with $223 million in Debt Redemptions Year to Date
-
Appendix 4C - Q1 FY23 Quarterly Cash Flow Report
-
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
-
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
-
Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders
Back to ATH Stock Lookup
